GoAI
Get started
Canopy Growth Corporation logo

Canopy Growth Corporation

CGC

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Latest quote

$1.08

$0.00 · 0.00%

Aug 21, 3:55 PM ET

CGC company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

68

Undervalued

Momentum

27

Weakening

Sentiment

51

Mixed

Risk resilience

29

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Canopy Growth Corporation (CGC), alongside its affiliated businesses, specializes in the cultivation, marketing, and retail of both cannabis and hemp-derived products. These offerings are designed for both recreational consumption and therapeutic uses, with its primary commercial reach extending across Canada, the United States, and Germany. The company structures its operations into two main divisions: Global Cannabis and a diverse portfolio of Other Consumer Products. Its extensive product range features dried cannabis flower, various extracts and concentrates, infused beverages, edible gummies, and vape cartridges. Canopy Growth distributes these items under numerous well-known brands, such as Tweed, 7ACRES, Martha Stewart CBD, and Spectrum Therapeutics, among others. Originally founded as Tweed Marijuana Inc., the enterprise adopted its current name, Canopy Growth Corporation, in September 2015. Established in 2009, the firm maintains its corporate headquarters in Smiths Falls, Canada.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
CA
CEO
Luc Mongeau
Listed since
Apr 7, 2014
Employees
1,128

Market position

Volume
5.42M
1× average
Average volume
5.41M
Average daily volume
Market cap
443.26M USD
Beta
2.41
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
3.85B CAD
EV / EBITDA
-20.46×
Earnings yield
-6.68%
Free cash flow yield
-1.77%

Profitability & efficiency

Return on equity
-37.69%
Return on assets
-23.50%
Return on invested capital
-7.38%

Financial health

Current ratio
3.34×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends131%-274%-680%-1085%Gross margin, FY2022: -39.40%Gross margin, FY2023: -19.06%Gross margin, FY2024: 27.22%Gross margin, FY2025: 29.56%Gross margin, FY2026: 24.48%Operating margin, FY2022: -214.17%Operating margin, FY2023: -789.34%Operating margin, FY2024: -76.97%Operating margin, FY2025: -43.55%Operating margin, FY2026: -25.69%Net margin, FY2022: -65.18%Net margin, FY2023: -983.68%Net margin, FY2024: -221.19%Net margin, FY2025: -222.35%Net margin, FY2026: -92.38%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2022 -39.40%. Gross margin FY2023 -19.06%. Gross margin FY2024 27.22%. Gross margin FY2025 29.56%. Gross margin FY2026 24.48%. Operating margin FY2022 -214.17%. Operating margin FY2023 -789.34%. Operating margin FY2024 -76.97%. Operating margin FY2025 -43.55%. Operating margin FY2026 -25.69%. Net margin FY2022 -65.18%. Net margin FY2023 -983.68%. Net margin FY2024 -221.19%. Net margin FY2025 -222.35%. Net margin FY2026 -92.38%.

Income trends

Revenue

284.6M CAD+5.80%

Operating income

−73.11M CAD+37.59%

Net income

−262.91M CAD+56.04%
Income trends across reported periods851.08M CAD−650.46M CAD−2.15B CAD−3.65B CADRevenue, FY2022: 475.7M CADRevenue, FY2023: 333.25M CADRevenue, FY2024: 297.15M CADRevenue, FY2025: 269M CADRevenue, FY2026: 284.6M CADOperating income, FY2022: −1.02B CADOperating income, FY2023: −2.63B CADOperating income, FY2024: −228.71M CADOperating income, FY2025: −117.14M CADOperating income, FY2026: −73.11M CADNet income, FY2022: −310.04M CADNet income, FY2023: −3.28B CADNet income, FY2024: −657.27M CADNet income, FY2025: −598.12M CADNet income, FY2026: −262.91M CADFY2022FY2023FY2024FY2025FY2026
Revenue FY2022 475.7M CAD. Revenue FY2023 333.25M CAD. Revenue FY2024 297.15M CAD. Revenue FY2025 269M CAD. Revenue FY2026 284.6M CAD. Operating income FY2022 −1.02B CAD. Operating income FY2023 −2.63B CAD. Operating income FY2024 −228.71M CAD. Operating income FY2025 −117.14M CAD. Operating income FY2026 −73.11M CAD. Net income FY2022 −310.04M CAD. Net income FY2023 −3.28B CAD. Net income FY2024 −657.27M CAD. Net income FY2025 −598.12M CAD. Net income FY2026 −262.91M CAD.
Metric (CAD)FY2026FY2025FY2024FY2023FY2022
Revenue284.6M CAD269M CAD297.15M CAD333.25M CAD475.7M CAD
Cost of goods sold214.93M CAD189.48M CAD216.26M CAD396.78M CAD663.11M CAD
Gross profit69.67M CAD79.51M CAD80.88M CAD−63.53M CAD−187.41M CAD
Research and development——4.61M CAD21.72M CAD32.26M CAD
Selling, general, and administrative122.93M CAD121.71M CAD180.59M CAD297.98M CAD361.1M CAD
Operating expenses142.78M CAD196.65M CAD309.6M CAD2.57B CAD831.39M CAD
Interest income10M CAD8.82M CAD16.24M CAD24.28M CAD6.6M CAD
Interest expense38.19M CAD74.57M CAD105.35M CAD126.16M CAD103.94M CAD
Depreciation and amortization36.47M CAD43.12M CAD53.18M CAD80.03M CAD110.94M CAD
Operating income−73.11M CAD−117.14M CAD−228.71M CAD−2.63B CAD−1.02B CAD
Net income−262.91M CAD−598.12M CAD−657.27M CAD−3.28B CAD−310.04M CAD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-0.88
FY2026
Latest fiscal-year revenue
284.6M CAD
FY2026 · +5.80% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend6.1-21.83-49.75-77.68FY22FY23FY24FY25FY26

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend496.37M413.69M331.01M248.32MFY22FY23FY24FY25FY26

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

27 ratings
Strong buy00%
Buy933%
Hold1141%
Sell726%
Strong sell00%

Corporate actions

Corporate action history

Stock split

Effective Dec 20, 2023

1:10

CGC peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding CGC

Funds reporting this stock among their holdings, ordered by reported position size.

Amplify Alternative Harvest ETF logoAmplify Alternative Harvest ETFMJ
Market value
9.48M
Weight
7.99%
AUM
118.56M USD
Expense ratio
1.12%
Price / 1D
$26.35+1.62%
AdvisorShares Pure Cannabis ETF logoAdvisorShares Pure Cannabis ETFYOLO
Market value
409.17K
Weight
1.13%
AUM
36.39M USD
Expense ratio
0.91%
Price / 1D
$3.06+3.03%
State Street SPDR S&P Emerging Markets Small Cap ETF logoState Street SPDR S&P Emerging Markets Small Cap ETFEWX
Market value
147.86K
Weight
0.02%
AUM
685.65M USD
Expense ratio
0.65%
Price / 1D
$72.22+0.25%
Avantis Emerging Markets ex-China Equity ETF logoAvantis Emerging Markets ex-China Equity ETFAVXC
Market value
51.78K
Weight
0.01%
AUM
445.33M USD
Expense ratio
0.33%
Price / 1D
$81.593+0.73%
Avantis Emerging Markets Value ETF logoAvantis Emerging Markets Value ETFAVES
Market value
38.23K
Weight
—
AUM
1.5B USD
Expense ratio
0.36%
Price / 1D
$65.16+0.51%
Avantis Emerging Markets Equity ETF logoAvantis Emerging Markets Equity ETFAVEM
Market value
17.28K
Weight
—
AUM
27.89B USD
Expense ratio
0.33%
Price / 1D
$94.24+0.75%
Avantis Emerging Markets Small Cap Equity ETF logoAvantis Emerging Markets Small Cap Equity ETFAVEE
Market value
12.12K
Weight
0.01%
AUM
122.3M USD
Expense ratio
0.42%
Price / 1D
$68.1949+0.35%
State Street SPDR S&P Emerging Markets ex-China ETF logoState Street SPDR S&P Emerging Markets ex-China ETFXCNY
Market value
2.24K
Weight
0.02%
AUM
9.88M USD
Expense ratio
0.19%
Price / 1D
$33.3219+0.99%

Continue in GoAI

Research CGC

research.disclaimer